(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 August 2019 (08.08.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/152232 A1

(51) International Patent Classification:
A61K 31/69 (2006.01) *A61K 47/06* (2006.01)
A61K 45/06 (2006.01) *A61K 47/10* (2017.01)

(21) International Application Number:
PCT/US2019/014524

(22) International Filing Date:
22 January 2019 (22.01.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/624,567 31 January 2018 (31.01.2018) US

(71) Applicant: **TWI PHARMACEUTICALS, INC.**; 4F, No. 41, Lane 221, Kang Chien Rd., Nei Hu Dist., Taipei 114 (TW).

(72) Inventor; and
(71) Applicant *(for US only)*: **LU, Guang-Wei** [US/US]; 42 Soho, Irving, CA 92612 (US).

(72) Inventors: **CHEN, Chih-Ming**; 4F, No. 41, Lane 221, Kang Chien Rd., Nei Hu Dist., Taipei 114 (TW). **LIAW, Ling-Ying**; 4F, No. 41, Lane 221, Kang Chien Rd., Nei Hu Dist., Taipei 114 (TW). **LIU, Fan-lun**; 4F, No. 41, Lane 221, Kang Chien Rd., Nei Hu Dist., Taipei 114 (TW). **LIAO, Shih-Fen**; 4F, No. 41, Lane 221, Kang Chien Rd., Nei Hu Dist., Taipei 114 (TW). **CHEN, Chou-Hsiung**; 4F, No. 41, Lane 221, Kang Chien Rd., Nei Hu Dist., Taipei 114 (TW). **KAO, Yu-Han**; 4F, No. 41, Lane 221, Kang Chien Rd., Nei Hu Dist., Taipei 114 (TW). **CHEN, Yu-Yin**; 4F, No. 41, Lane 221, Kang Chien Rd., Nei Hu Dist., Taipei 114 (TW).

(74) Agent: **POLYAKOV, Mark, V.** et al.; Wood, Phillips, Katz, Clark & Mortimer, 500 West Madison Street, Suite 1130, Chicago, IL 60661 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: TOPICAL FORMULATIONS COMPRISING TOFACITINIB

(57) Abstract: A topical formulation comprising (a) a therapeutically effective amount of tofacitinib; (b) at least one solvent; and (c) optionally one or more other pharmaceutically acceptable excipients is provided. Also provided is a method for treating and/or preventing autoimmune diseases in a subject administering said topical formulation.

WO 2019/152232 A1